First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

ConclusionFirst-line treatment with a PD-1 blocking antibody might be associated with longer OS than first-line inhibition of the MAPK pathway in patients with advanced melanoma harboring mutant BRAF. These hypothesis-generating data need to be confirmed or rejected in prospective, randomized trials.

Source: Cancer Immunology, Immunotherapy - February 26, 2019 Category: Cancer & Oncology Source Type: research